Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced that the first patient has been dosed in its ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Recently in the Journal of Clinical Oncology, Monk et al 1 reported the final overall survival (OS) results of the KEYNOTE-826 study, which confirmed that pembrolizumab plus chemotherapy, with or ...

This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.